Objective A meta-analysis of the efficacy and safety of indobufen compared to aspirin in treating patients with acute ischemic stroke.Methods The databases including CNKI,Wanfang Data,PubMed,Cochrane Library and Embase were searched for the randomized controlled trials about indobufen(trial group)and aspirin(control group)were collected from the inception to April 20,2023.According to the inclusion and exclusion criteria,two researchers independently screened the literature,extracted the data and evaluated the quality of the included studies,and used RevMan 5.4 software for Meta-analysis.Results Meta-analysis showed that the total adverse reaction rate of trial group lower than control group[RR(95％CI):0.28(0.14,0.56),P=0.000 3].There was no significant difference of the two groups in NIHSS score[MD(95％CI):-1.30(-2.97,0.38),P=0.13],rate of platelet aggregation induced by AA[MD(95％CI):-1.70(-5.76,2.37),P=0.41],rate of platelet aggregation induced by ADP[MD(95％CI):-1.76(-7.41,3.90),P=54],total clinical effective rate[RR(95％CI):1.05(0.97,1.13),P=0.26].Conclusion Indobufen has similar clinical efficacy to aspirin in the treatment of patients with acute ischemic stroke however,the incidence of indobufen was significantly lower than that of aspirin in gastrointestinal reactions,dizziness,bleeding,rash and other adverse events.
维普
万方数据